Latest News

Lenvatinib May Be Effective for Patients With, Without Prior VEGF Therapy Exposure

Lenvatinib May Be Effective for Patients With, Without Prior VEGF Therapy Exposure

In thyroid cancer with and without prior exposure to VEGF therapy, the response rates and survival for lenvatinib have prompted further investigation.

Radiotherapy, No Treatment After ABVD Effective for Early-Stage Hodgkin's Lymphoma

Radiotherapy, No Treatment After ABVD Effective for Early-Stage Hodgkin's Lymphoma

Early-stage Hodgkin's lymphoma and negative PET findings had good prognosis either with or without consolidation radiotherapy.

Genomic Characterization for African-Americans with NSCLC May Not Differ

Genomic Characterization for African-Americans with NSCLC May Not Differ

Non-small cell lung cancer (NSCLC) patients with African-American ancestry may not differ from European backgrounds in somatic driver mutations.

Hodgkin's Lymphoma Survivors Face Higher Cardiovascular Risks

Hodgkin's Lymphoma Survivors Face Higher Cardiovascular Risks

Physicians and patients should be aware of the persistently increased risk of cardiovascular diseases throughout life after Hodgkin's lymphoma.

Astellas Launches Antifungal Cresemba for Invasive Aspergillosis, Mucormycosis

Astellas Launches Antifungal Cresemba for Invasive Aspergillosis, Mucormycosis

Astellas has announced the launch of Cresemba (isavuconazonium sulfate) for treatment of invasive aspergillosis and mucormycosis.

FOLFIRI, Bevacizumab 10 mg Not More Effective Than 5 mg for Colorectal Cancer

FOLFIRI, Bevacizumab 10 mg Not More Effective Than 5 mg for Colorectal Cancer

Bevacizumab 10mg/kg plus FOLFIRI as second-line treatment did not prolong progression-free survival compared with 5mg/kg in colorectal cancer.

Pembrolizumab May Be More Effective, Safer Than Ipilimumab for Advanced Melanoma

Pembrolizumab May Be More Effective, Safer Than Ipilimumab for Advanced Melanoma

Pembrolizumab better prolonged progression-free survival and overall survival than did ipilimumab in advanced melanoma.

Oral S-1 May Be Non-Inferior to Docetaxel for Non-Small Cell Lung Cancer

Oral S-1 May Be Non-Inferior to Docetaxel for Non-Small Cell Lung Cancer

Oral S-1 with cisplatin may not be inferior compared to docetaxel with cisplatin in advanced non-small cell lung cancer (NSCLC).

Cyramza Plus FOLFIRI Approved for Metastatic Colorectal Cancer

Cyramza Plus FOLFIRI Approved for Metastatic Colorectal Cancer

The FDA announced approval of CYRAMZA (ramucirumab) for use in combination with FOLFIRI for metastatic colorectal cancer.

POMALYST Meets Accelerated Approval Requirements for Multiple Myeloma

POMALYST Meets Accelerated Approval Requirements for Multiple Myeloma

POMALYST for relapsed/refractory multiple myeloma has met its accelerated approval requirements.

Breast Cancer Patients Eligible for Lumpectomy Still Choose Mastectomy

Breast Cancer Patients Eligible for Lumpectomy Still Choose Mastectomy

Many breast cancer patients who are eligible for breast-conserving surgery still choose to have the entire breast removed.

Colorectal Cancer Screening in Older Adults Often Inappropriate

Colorectal Cancer Screening in Older Adults Often Inappropriate

Older adults with limited life expectancy (LE) frequently receive colorectal cancer (CRC) screening.

Two Novel Technologies Show Promise in Cancer Treatment

Two Novel Technologies Show Promise in Cancer Treatment

Two new devices may eventually lead to more accurate, less toxic methods of predicting how well specific cancer drug might work.

Oophorectomy Linked to Better Survival in BRCA1 Breast Cancer

Oophorectomy Linked to Better Survival in BRCA1 Breast Cancer

Oophorectomy is associated with a decrease in mortality in women with breast cancer and a BRCA1 mutation.

In Breast Cancer, Self-Reported Health Predicts Survival

In Breast Cancer, Self-Reported Health Predicts Survival

For older women with breast cancer, low self-rated health (SRH) and limited walking ability predict worse all-cause survival at five and 10 years.

Second Primaries in Nearly Quarter of Metastatic Prostate Cancer Cases

Second Primaries in Nearly Quarter of Metastatic Prostate Cancer Cases

More than one-quarter of patients with metastatic prostate cancer present with a synchronous second primary malignancy.

Nivolumab, Ipilimumab More Effective Than Ipilimumab Alone for Melanoma

Nivolumab, Ipilimumab More Effective Than Ipilimumab Alone for Melanoma

Response rate and progression-free survival in untreated advanced melanoma significantly greated with nivolumab plus ipilimumab.

Pembrolizumab Safe, Shows Activity for Advanced Lung Cancer

Pembrolizumab Safe, Shows Activity for Advanced Lung Cancer

Pembrolizumab had an acceptable side-effect profile and showed antitumor activity in patients with advanced non-small-cell lung cancer (NSCLC).

Better Colorectal Cancer Surgery Outcomes with Higher-Volume Providers

Better Colorectal Cancer Surgery Outcomes with Higher-Volume Providers

Patients with colorectal cancer who undergo surgery at higher-volume providers may face better outcomes.

Outcome of Salpingectomy Alone for Ovarian Cancer Evaluated

Outcome of Salpingectomy Alone for Ovarian Cancer Evaluated

Salpingectomy alone may be a risk management option for women at hereditary risk of ovarian cancer.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs